Archive for November, 2012

Flucelvax, the first cell-culture vaccine in the US to help protect against seasonal influenza

Tuesday, November 20th, 2012 (last updated)

Flucelvax utilizes full-scale cell-culture manufacturing technology, an alternative production method to traditional egg-based production. Cell-culture technology utilizes a well-characterized mammalian cell line rather than chicken eggs to grow virus strains.

The production occurs in a closed, sterile, controlled environment, which significantly reduces the risk of potential impurities. Flucelvax does not contain any preservatives, such as thimerosal, or antibiotics.

Cell-culture technology enables rapid response to urgent public health needs such as a pandemic within weeks. Traditional influenza vaccine production depends on a large number of fertilized chicken eggs to grow virus strains and requires many months for organization of egg supplies, virus incubation and actual production before the vaccine is delivered to physicians or pharmacies. Cell-culture technology is successfully used to manufacture other vaccines, including those distributed during the H1N1 pandemic, as well as vaccines for polio, rubella and hepatitis A.

“The approval of Flucelvax is an important milestone for our influenza franchise and brings an innovative vaccine to the US,” said Andrin Oswald, Division Head, Novartis Vaccines and Diagnostics. “Modern cell-culture technology will likely become the new standard for influenza vaccine production and we are proud to lead the way.”

Source:
Novartis

99.9999% of vaccinated US babies have no serious side effects or injury

Tuesday, November 20th, 2012 (last updated)

99.9999% of vaccinated US babies have no serious side effects or injury

According to the US Census Bureau, there are approximately 4 million babies born in the USA every year since 1960. (Source)

The National Vaccine Injury Compensation program was created in 1989, in the USA.  “Since the first Vaccine Injury Compensation claims were made in 1989, 3,050 compensation payments have been made, $2,354,402,849.25 disbursed to petitioners and $92,790,487.47 paid to cover attorney’s fees and other legal costs. To date, 9,637 claims have been dismissed. Of those, 3,125 claimants were paid $51,671,299.21 to cover attorney’s fees and other legal costs.” (Source)

During this time period, since 1989, approximately 92 million babies have been born and almost all of them are vaccinated.  68% of infants born in 2011 had the birth dose of Hep B.  95% of infants born in 2011 had three doses of the DTaP vaccine. 91% of one year olds had the MMR in 2011. (Source)
If you add all these numbers up, almost 100 million children have been vaccinated in the United States, since 1989.  Only 14,000 have filed claims. This means that 99.999% of children vaccinated in the USA since 1989 have not had a serious injury.  That is a remarkable success rate.

And no one denies that vaccines can cause injury. But it is far more common to experience a serious complication from a disease than a serious side effect from a vaccine injury.

Source:
Informed Parents Of Vaccinated Children (blog)

How many doses of influenza vaccine do children need in the 2012-2013 influenza season?

Monday, November 19th, 2012 (last updated)

How many doses of influenza vaccine do children need in the 2012-2013 influenza season? Click here

Source:
Immunize.org

If you think whooping cough is no big deal in 2012, think again

Sunday, November 18th, 2012 (last updated)

Whooping cough is a dangerous disease that can be catastrophic for infants. This is one family’s story of their newborn’s battle against whooping cough and their message to the community. To learn more about what you can do to prevent whooping cough go to www.silencewhoopingcough.org.

Source:
GroupHealth

Meningitis B vaccine set for European licence

Saturday, November 17th, 2012 (last updated)

Meningitis B is the most common and deadliest form of meningitis on the country, affecting in the UK an average of 1,870 people a year, many of them children – and resulting in death for one in 10 sufferers.

The approval of the new 4CMenB vaccine, which is developed by pharmaceutical company Novartis, has been hailed as the “biggest leap forward in the field in the three decades” by the charity Meningitis UK.

It received a “positive opinion” verdict from the European Medicines Agency (EMA), meaning that the vaccine is considered safe and effective. It will be the first Meningitis B vaccine approved for use in the UK, which has one of the highest incidence rates in the world.

One in four sufferers are left with life changing after-effects, such as brain damage and limb loss, with children under five most at risk from the disease. It can sometimes kill babies and toddlers in under four hours.

Meningitis UK wants the vaccine to be introduced into the Government’s routine immunisation schedule as soon as possible, so it will be automatically given to children. The jab is recommended for those aged two months and older.

The charity’s founder Steve Dayman, who lost his baby son to meningitis and septicaemia in 1982, said: “This is a landmark moment in the fight against meningitis – I have waited three decades to hear this.

“It is vital that the vaccine is introduced in the UK immunisation schedule as soon as possible. It will save countless lives and prevent many people enduring the suffering caused by this devastating disease.

“We will be campaigning hard to make the Government introduce it.”

The decision on whether to introduce the vaccine to the immunisation schedule will be made by the Joint Committee on Vaccination and Immunisation (JCVI), who advise the Government on vaccination.

Source:
The Telegraph

Vaccine-preventabel disease – The forgotten story: “Facing meningitis”

Saturday, November 17th, 2012 (last updated)

Source:
Texas Childrens Video

UK babies to get vaccine against highly infectious rotavirus

Friday, November 16th, 2012 (last updated)

Babies are to be vaccinated against a highly-infectious bug that is one of the most common causes of diarrhoea in children.
From September 2013, infants aged between two and four months will be immunised against rotavirus, which causes diarrhoea, vomiting, abdominal pain, fever and dehydration.
At present, almost every child will have had the viral infection by the age of five. It is the most common cause of gastroenteritis in young children and babies.
The Department of Health said the move will mean thousands of young children will be spared hospital stays and hundreds of thousands of GP visits.
At present, the virus causes 140,000 diarrhoea cases a year in under-fives across the UK, and leads to around 14,000 hospital stays.
Vaccination experts believe the immunisation programme will halve the number of vomiting and diarrhoea cases caused by rotavirus and there could be 70% fewer hospital stays as a result.
Children will receive the vaccine, to be given orally as two separate doses of liquid drops, as part of their routine vaccination programme.
Professor David Salisbury, Director of Immunisation at the DoH, said: “Rotavirus spreads very easily.
”Many people think of diarrhoea as something that all children get and that you have to put up with. But there is a way to protect children from this.
”I’d encourage all parents of young children to accept this vaccine when the programme begins next year.”

Source:
Sandwellnews

Vaccine patch revolution

Thursday, November 15th, 2012 (last updated)

Mark Kendall, an Australian bio-engineer, is developing a “Nanopatch” to replace needles in vaccination. The technology has the potential to save millions of lives in the developing world by making the process painless, safer, cheaper and more effective.

The traditional syringe-and-needle method of vaccination is expensive due to the need to keep the vaccines inside the “cold chain”. Professor Kendall’s patch is coated with dry vaccine so no refrigeration is needed.

Source:
World of Rolex

Health officials in New Mexico launch whooping cough campaign

Wednesday, November 14th, 2012 (last updated)

Source:
KRQE

Trust in vaccines & Why it matters

Tuesday, November 13th, 2012 (last updated)

The Forum event at Harvard School of Public Health examined the importance of immunization, the safety of vaccines, and the consequences of vaccine hesitancy.

In this clip, Barry Bloom, former Dean of the Harvard School of Public Health, discusses considerations when addressing the concerns of parents.

Watch the entire video at www.ForumHSPH.org.

Source:
Forum at Harvard School of Public Health